ClinicalTrials.gg
CompletedNCT01080300Breeze3Updated May 1, 2020Results posted

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

A Phase 3 interventional study of Gabapentin Extended Release and Placebo in Hot Flashes, sponsored by Depomed. Completed at 66 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Depomed · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.

Enrollment
Largest of 10
600 · median 160
Started
2010
the only one that year
Phase 3
6 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
4 of 11
Depomed

Among the 11 studies testing gabapentin in Hot Flashes, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 3, and was the 9th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing gabapentin in Hot Flashes as a file.
02

Study summary

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women

Read the detailed description

The primary study objective is to assess the efficacy of G-ER dosed at 1800mg daily (600mg AM, 1200mg PM), compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women at weeks 4 \& 12 of the efficacy treatment period, compared with baseline.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Hot Flushes
  • Vasomotor Symptoms
  • Menopausal Hot Flashes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy, women who seek treatment for hot flashes
  • Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment
  • Patients must be experiencing moderate to severe hot flashes
  • Patients must be able to sign the
  • Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary

Other inclusions apply.

Exclusion criteria

Exclusion Criteria:

  • Patients with to Gabapentin
  • Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss
  • Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.
  • Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms

Other exclusions apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Gabapentin Extended Release

    Active treatment

    Drug: Gabapentin Extended Release

  • Other
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

    G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.

    Time frame: Baseline, Week 4, and Week 12

  2. G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

    G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.

    Time frame: Baseline, Week 4, and Week 12

Secondary outcomes

  1. G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

    G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline.

    Time frame: Baseline, Week 24

  2. G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

    G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 24 of the efficacy treatment period compared with Baseline.

    Time frame: Baseline, Week 24

  3. Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

    Proportion of patients who were categorized as "very much" or "much improved" for PGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".

    Time frame: Week 12 and Week 24

  4. Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

    Proportion of patients who were categorized as "very much" or "much improved" in CGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".

    Time frame: Week 12 and Week 24

  5. Percent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes

    Time frame: Baseline, Week 12, and Week 24

  6. Percent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes

    Time frame: Baseline, Week 12, and Week 24

  7. Change From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.

    Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference)

    Time frame: Baseline, Week 4, Week 12, and Week 24

  8. Changes From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.

    Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)).

    Time frame: Baseline, Week 4, Week 12, and Week 24

  9. Changes From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.

    4 sub-categories each scored individually: Minimum value = 1, maximum value = 8. Overall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8). Lower scores indicate better outcome (ie, less severity)

    Time frame: Baseline, Week 4, Week 12, and Week 24

  10. Safety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).

    Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation. Higher counts without suicidal ideation = better outcome.

    Time frame: Week 4, Week 12, Week 24/Early Termination, Week 28

07

Results

Posted Mar 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneG-ER 1800 mgSugar Pill
Started300295
Completed206191
Not completed94104
Withdrew: Adverse event4935
Withdrew: Lack of efficacy1215
Withdrew: Protocol violation713
Withdrew: Lost to follow-up106
Withdrew: Death01
Withdrew: Withdrawal by subject1228
Withdrew: Reasons not specified46

Outcome measures

PrimaryG-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.

Time frame:
Baseline, Week 4, and Week 12
Reported as:
Least squares mean · hot flashes
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.
hot flashesG-ER 1800 mgSugar Pill
Baseline LOCF Average Daily Frequency at Week 4-6.72 (-7.24 to -6.19)-5.01 (-5.54 to -4.49)
Baseline LOCF Average Daily Frequency at Week 12-7.64 (-8.21 to -7.07)-6.50 (-7.07 to -5.94)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · Based on Van Eltereen · p = 0.0003 (P-value for the test of difference of the least square mean change from baseline between Gabapentin ER 1800 mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -1.70 · 95% CI -2.31 to -1.09Based on ANCOVA
  • G-ER 1800 mg vs Sugar Pill · Based on Van Elteren · p = 0.1000 (P-value for the test of difference of the least square mean change from baseline between Gabapentin ER 1800 mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -1.14 · 95% CI -1.80 to -0.48Based on ANCOVA
PrimaryG-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.

Time frame:
Baseline, Week 4, and Week 12
Reported as:
Least squares mean · scores on a scale
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.
scores on a scaleG-ER 1800 mgSugar Pill
Baseline LOCF Average Daily Severity at Week 4-0.42 (-0.51 to -0.33)-0.22 (-0.31 to -0.13)
Baseline LOCF Average Daily Severity at Week 12-0.65 (-0.77 to -0.52)-0.46 (-0.58 to -0.34)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · Based on Van Elteren · p = <0.0001 (P-value for the test of difference of the least square mean change from baseline between Gabapentin ER 1800 mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -0.21 · 95% CI -0.31 to -0.10Based on ANCOVA
  • G-ER 1800 mg vs Sugar Pill · Based on Van Elteren · p = 0.0004 (P-value for the test of difference of the least square mean change from baseline between Gabapentin ER 1800 mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -0.19 · 95% CI -0.33 to -0.04Based on ANCOVA
SecondaryG-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · hot flashes
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.
hot flashesG-ER 1800 mgSugar Pill
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.-8.99 (-9.71 to -8.27)-7.91 (-8.62 to -7.19)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · Based on Van Elteren · p = 0.1510 · Mean difference (net): -1.08 · 95% CI -1.98 to -0.19Based on ANCOVA
SecondaryG-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 24 of the efficacy treatment period compared with Baseline.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · scores on a scale
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.
scores on a scaleG-ER 1800 mgSugar Pill
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.-0.86 (-1.03 to -0.69)-0.64 (-0.81 to -0.47)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · Van Elteren · p = 0.0004 · Mean difference (net): -0.22 · 95% CI -0.44 to -0.00Based on ANCOVA
SecondaryPatient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

Proportion of patients who were categorized as "very much" or "much improved" for PGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".

Time frame:
Week 12 and Week 24
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.
ParticipantsG-ER 1800 mgSugar Pill
Baseline LOCF Proportion at Week 12173130
Baseline LOCF Proportion at Week 24156114
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · 2-sample Z test · p = 0.0008 · Risk difference (rd): 13.6 · 95% CI 5.7 to 21.6Risk difference defined as treatment difference in proportion of responders.
  • G-ER 1800 mg vs Sugar Pill · 2-sample Z test · p = 0.0009 · Risk difference (rd): 13.4 · 95% CI 5.5 to 21.3Risk difference defined as treatment difference in proportion of responders.
SecondaryClinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

Proportion of patients who were categorized as "very much" or "much improved" in CGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".

Time frame:
Week 12 and Week 24
Reported as:
Count of participants · Participants
Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.
ParticipantsG-ER 1800 mgSugar Pill
Baseline LOCF Proportion at Week 12173122
Baseline LOCF Proportion at Week 24159124
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · 2-sample Z test · p = <0.0001 · Risk difference (rd): 16.4 · 95% CI 8.4 to 24.3Risk difference defined as treatment difference in proportion of responders.
  • G-ER 1800 mg vs Sugar Pill · 2-sample Z test · p = 0.0070 · Risk difference (rd): 11.0 · 95% CI 3.0 to 19.0Risk difference defined as treatment difference in proportion of responders.
SecondaryPercent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Count of participants · Participants
Percent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes
ParticipantsG-ER 1800 mgSugar Pill
Baseline LOCF Proportion at Week 12125101
Baseline LOCF Proportion at Week 24146122
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · two-sample Z test · p = 0.0609 · Risk difference (rd): 7.5 · 95% CI -0.3 to 15.2Risk difference defined as treatment difference in proportion of responders.
  • G-ER 1800 mg vs Sugar Pill · two-sample Z test · p = 0.0720 · Risk difference (rd): 7.3 · 95% CI -0.7 to 15.3Risk difference defined as treatment difference in proportion of responders.
SecondaryPercent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Count of participants · Participants
Percent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes
ParticipantsG-ER 1800 mgSugar Pill
Baseline LOCF Average Daily Score at Week 124836
Baseline LOCF Average Daily Score at Week 246248
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · two-sample Z test · p = 0.1825 · Risk difference (rd): 3.8 · 95% CI -1.8 to 9.4Risk difference defined as treatment difference in proportion of responders.
  • G-ER 1800 mg vs Sugar Pill · two-sample Z test · p = 0.1662 · Risk difference (rd): 4.4 · 95% CI -1.8 to 10.7Risk difference defined as treatment difference in proportion of responders.
SecondaryChange From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.

Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference)

Time frame:
Baseline, Week 4, Week 12, and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.
units on a scaleG-ER 1800 mgSugar Pill
Change from Baseline to Week 4: LOCF daily rating-2.67 (-3.00 to -2.33)-1.31 (-1.64 to -0.97)
Change from Baseline to Week 12: LOCF daily rating-3.09 (-3.47 to -2.71)-2.17 (-2.56 to -1.79)
Change from Baseline to Week 24: LOCF daily rating-3.15 (-3.56 to -2.75)-2.20 (-2.60 to -1.80)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (The P value (versus placebo) for the pairwise test of difference of the LS mean change from Baseline between the G-ER 1800-mg and placebo-treatment groups was based on the F test of type III analysis.) · Mean difference (net): -1.36 · 95% CI -1.75 to -0.97No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (The P value (versus placebo) for the pairwise test of difference of the LS mean change from Baseline between the G-ER 1800-mg and placebo-treatment groups was based on the F test of type III analysis.) · Mean difference (net): -0.92 · 95% CI -1.36 to -0.47No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (The P value (versus placebo) for the pairwise test of difference of the LS mean change from Baseline between the G-ER 1800-mg and placebo-treatment groups was based on the F test of type III analysis.) · Mean difference (net): -0.95 · 95% CI -1.42 to -0.49No multiplicity adjustments were made for secondary efficacy outcomes
SecondaryChanges From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.

Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)).

Time frame:
Baseline, Week 4, Week 12, and Week 24
Reported as:
Least squares mean · scores on a scale
Changes From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.
scores on a scaleG-ER 1800 mgSugar Pill
Change from Baseline to Week 4: LOCF ISI rating-6.47 (-7.67 to -5.82)-4.13 (-5.04 to -3.21)
Change from Baseline to Week 12: LOCF ISI rating-7.02 (-7.96 to -6.09)-5.17 (-6.10 to -4.25)
Change from Baseline to Week 24: LOCF ISI rating-6.71 (-7.65 to -5.77)-4.95 (-5.88 to -4.01)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (The P value (versus placebo) for the pairwise test of difference of the LS mean change from Baseline between the G-ER 1800-mg and placebo-treatment groups was based on the F test of type III analysis.) · Mean difference (net): -2.62 · 95% CI -3.67 to -1.56No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0007 (The P value (versus placebo) for the pairwise test of difference of the LS mean change from Baseline between the G-ER 1800-mg and placebo-treatment groups was based on the F test of type III analysis.) · Mean difference (net): -1.85 · 95% CI -2.92 to -0.78No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0014 · Mean difference (net): -1.76 · 95% CI -2.84 to -0.69No multiplicity adjustments were made for secondary efficacy outcomes
SecondaryChanges From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.

4 sub-categories each scored individually: Minimum value = 1, maximum value = 8. Overall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8). Lower scores indicate better outcome (ie, less severity)

Time frame:
Baseline, Week 4, Week 12, and Week 24
Reported as:
Least squares mean · scores on a scale
Changes From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.
scores on a scaleG-ER 1800 mgSugar Pill
Baseline LOCF MENQOL score at Week 4-0.91 (-1.06 to -0.77)-0.71 (-0.85 to -0.57)
Baseline LOCF MENQOL score at Week 12-1.01 (-1.16 to -0.87)-0.87 (-1.01 to -0.72)
Baseline LOCF MENQOL score at Week 24-1.01 (-1.17 to -0.86)-0.96 (-1.11 to -0.81)
Statistical analysis
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0137 (The p-value (vs. Placebo) for the test of difference of the LS mean change from baseline between Gabapentin ER 1800mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -0.21 · 95% CI -0.37 to -0.04No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0872 (The p-value (vs. Placebo) for the test of difference of the LS mean change from baseline between Gabapentin ER 1800mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -0.14 · 95% CI -0.31 to 0.02No multiplicity adjustments were made for secondary efficacy outcomes
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.5607 (The p-value (vs. Placebo) for the test of difference of the LS mean change from baseline between Gabapentin ER 1800mg and placebo group is based on the F-test of Type III analysis.) · Mean difference (net): -0.05 · 95% CI -0.23 to 0.13No multiplicity adjustments were made for secondary efficacy outcomes
SecondarySafety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).

Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation. Higher counts without suicidal ideation = better outcome.

Time frame:
Week 4, Week 12, Week 24/Early Termination, Week 28
Reported as:
Count of participants · Participants
Safety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).
ParticipantsGabapentin Extended ReleasePlacebo
Patients Taking C-SSRS at Week 4 — With Suicidal Ideation00
Patients Taking C-SSRS at Week 4 — Without Suicidal Ideation260257
Patients Taking C-SSRS at Week 12 — With Suicidal Ideation10
Patients Taking C-SSRS at Week 12 — Without Suicidal Ideation224215
Patients Taking C-SSRS at Week 24/EarlyTermination — With Suicidal Ideation01
Patients Taking C-SSRS at Week 24/EarlyTermination — Without Suicidal Ideation271266
Patients Taking C-SSRS at Week 28 — With Suicidal Ideation10
Patients Taking C-SSRS at Week 28 — Without Suicidal Ideation256243

Adverse events

Collected over Adverse events collected for a total of 28-42 weeks: from after signing the informed consent to the end of the study (Week 28).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-ER 1800 mg—4/300 (1.3%)102/300 (34%)
Sugar Pill—7/295 (2.4%)53/295 (18%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventG-ER 1800 mgSugar Pill
Acute myocardial infarctionCardiac disorders0/3001/295
PalpitationsCardiac disorders0/3001/295
Acute sinusitisInfections and infestations0/3001/295
Bronchitis acuteInfections and infestations0/3001/295
Pneumonia primary atypicalInfections and infestations0/3001/295
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/3001/295
Haemorrhagic strokeNervous system disorders0/3001/295
AsthmaRespiratory, thoracic and mediastinal disorders0/3001/295
HypertensionVascular disorders0/3001/295
AnaemiaBlood and lymphatic system disorders1/3000/295
Most frequent other events
Most frequent other events
EventG-ER 1800 mgSugar Pill
DizzinessNervous system disorders38/30010/295
HeadacheNervous system disorders28/30024/295
SomnolenceNervous system disorders18/3008/295
Upper respiratory tract infectionInfections and infestations18/30011/295

Baseline characteristics

Intent-to-treat (ITT) Population

Age, Continuous
Age, Continuous(years)G-ER 1800 mgSugar PillTotal
Mean54.0 ± 6.154.0 ± 6.054.0 ± 6.1
Age, Customized
Age, Customized(participants)G-ER 1800 mgSugar PillTotal
< 65 years280282562
>=65 years191231
Sex: Female, Male
Sex: Female, Male(Participants)G-ER 1800 mgSugar PillTotal
Female299294593
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)G-ER 1800 mgSugar PillTotal
White215197412
Black7482156
Asian123
Hispanic9918
Other044
Frequency of hot flashes
Frequency of hot flashes(hot flashes)G-ER 1800 mgSugar PillTotal
Mild1.5 ± 2.81.5 ± 3.31.5 ± 3.1
Moderate6.4 ± 5.36.1 ± 4.96.3 ± 5.1
Severe7.1 ± 10.66.5 ± 5.46.8 ± 8.4
08

Study locations

66 sites
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Berkeley, California, United States
  • Roseville, California, United States
  • San Diego, California, United States
  • Denver, Colorado, United States
  • Danbury, Connecticut, United States
  • Milford, Connecticut, United States
  • Brooksville, Florida, United States
  • Clearwater, Florida, United States
  • DeLand, Florida, United States
  • Gainesville, Florida, United States
  • Naples, Florida, United States
  • New Port Richey, Florida, United States
  • North Miami, Florida, United States
  • Orlando, Florida, United States
  • Decatur, Georgia, United States
  • Idaho Falls, Idaho, United States
  • Indianapolis, Indiana, United States
  • South Bend, Indiana, United States
  • Overland Park, Kansas, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Paw Paw, Michigan, United States
  • Brooklyn Center, Minnesota, United States
  • Las Vegas, Nevada, United States
  • Reno, Nevada, United States
  • Moorestown, New Jersey, United States
  • Plainsboro, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Charlotte, North Carolina, United States
  • New Bern, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Fargo, North Dakota, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Kettering, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • West Reading, Pennsylvania, United States
  • Wexford, Pennsylvania, United States
  • Warwick, Rhode Island, United States
  • Anderson, South Carolina, United States
  • Columbia, South Carolina, United States
  • Goose Creek, South Carolina, United States
  • Greer, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Chattanooga, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Lake Jackson, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Charlottesville, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
09

References and documents

Publications

  • Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M; Breeze 3 Investigators. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause. 2014 Jun;21(6):567-73. doi: 10.1097/GME.0b013e3182a7c073. PubMed 24149930 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 4, 2010
Start
Aug 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Mar 26, 2014
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01080300
Lead sponsor
Depomed
Responsible party
Sponsor
First posted
Mar 4, 2010
Start date
Aug 2010
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Mar 26, 2014
Last update
May 1, 2020

Study contacts

Rekha Sathyanarayana
study director · Depomed

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion